Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

CRISPR Therapeutics AG (CRSP)

Biological Products, (no Disgnostic Substances)

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

BAARERSTRASSE 14
ZUG, V8

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/19/2016

Market Cap

4,079,556,780

Shares Outstanding

79,430,000

Weighted SO

79,432,446

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

BEAM --.--%

EDIT --.--%

CRBU --.--%

VERV --.--%

NTLA --.--%

FATE --.--%

REGN --.--%

NVO --.--%

SRPT --.--%

Beta

1.6950

Last Div

0.0000

Range

37.55-91.1

Chg

-0.9500

Avg Vol

1329766

Mkt Cap

4079556780

Exch

NASDAQ

Country

CH

Phone

41 41 561 32 77

DCF Diff

84.3034

DCF

-36.4132

Div Yield

0.0000

P/S

20.2942

EV Multiple

-11.2509

P/FV

2.0534

Div Yield %

0.0000

P/E

-15.3034

PEG

-260.1994

Payout

0.0000

Current Ratio

15.7281

Quick Ratio

15.7281

Cash Ratio

3.7902

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

22.6679

CCC

-22.6679

Gross Margin

0.2429

Op Margin

-1.7644

Pretax Margin

-1.3091

Net Margin

-1.3223

Eff Tax Rate

-0.0070

ROA

-0.1136

ROE

-0.1385

ROCE

-0.1603

NI/EBT

1.0101

EBT/EBIT

0.7419

EBIT/Rev

-1.7644

Debt Ratio

0.0989

D/E

0.1168

LT Debt/Cap

0.0978

Total Debt/Cap

0.1046

Int Coverage

-19.9334

CF/Debt

-0.5264

Equity Multi

1.1812

Rec Turnover

0.0000

Pay Turnover

16.1021

Inv Turnover

0.0000

FA Turnover

0.6894

Asset Turnover

0.0859

OCF/Share

-1.4338

FCF/Share

-1.4842

Cash/Share

23.5704

OCF/Sales

-0.6057

FCF/OCF

1.0352

CF Coverage

-0.5264

ST Coverage

-7.4013

CapEx Coverage

-28.4218

Div&CapEx Cov

-28.4218

P/BV

2.0534

P/B

2.0534

P/S

20.2942

P/E

-15.3034

P/FCF

-32.3664

P/OCF

-33.4079

P/CF

-33.4079

PEG

-260.1994

P/S

20.2942

EV Multiple

-11.2509

P/FV

2.0534

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Jul 21, 04:07 3 Monster Stocks in the Making to Buy Right Now The Motley Fool May 09, 21:17 Why Recursion Pharmaceuticals Stock Plummeted 24% This Week The Motley Fool Apr 20, 13:15 5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years The Motley Fool Mar 22, 20:04 2 Beaten-Down Stocks to Buy on the Dip The Motley Fool Mar 19, 22:10 2 No-Brainer Biotech Stocks to Buy Right Now The Motley Fool Dec 22, 17:25 This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy? The Motley Fool Nov 17, 12:05 Is It Too Late to Buy Viking Therapeutics Stock? The Motley Fool Oct 12, 12:30 2 Biotech Stocks That Are Screaming Buys This Month The Motley Fool Jan 23, 09:30 1 Setback and 1 Opportunity for CRISPR Therapeutics Stock The Motley Fool Jan 22, 09:00 If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 08:00 Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics The Motley Fool Jan 20, 06:50 3 High-Flying Stocks That Could Soar Even More in 2024 Zacks Investment Research Jan 19, 18:15 CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 19, 18:15 CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 19, 18:15 CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 19, 18:15 CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know Zacks Investment Research Jan 19, 18:15 CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

Revenue Product Segmentation